AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers $3.5 billion each year.
Dec 06, 2014, 08:43 AM IST